RVPH — Reviva Pharmaceuticals Holdings Share News
0.000.00%
Last trade - 00:00Reviva Pharmaceuticals Holdings, Inc. expected to post a loss of 22 cents a share - Earnings Preview
Brief: Reviva Pharmaceuticals Announces Letter To Shareholders
U.S. STOCKS ON THE MOVE-Trip.com, Verizon Communications, Netflix
U.S. STOCKS ON THE MOVE-Reviva, AbCellera, Verizon
Reviva rises on positive schizophrenia drug interaction trial data
Brief: Reviva Pharmaceuticals Announces Positive Safety Data From Drug-Drug Interaction Clinical Study Of Brilaroxazine
Brief: Reviva Announces Canadian Composition Of Matter Patent For RP1208
Brief: Reviva Pharmaceuticals Holdings Inc Reports Third Quarter 2022 Financial Results
Reviva Pharma up on patient enrollment updates in late-stage study
Brief: Reviva Pharmaceuticals Announces Global Enrollment Update For Phase 3 Study Evaluating Brilaroxazine For Schizophrenia
Brief: Reviva Pharmaceuticals Holdings, Inc. Announces $8.5 Million Registered Direct Offering And Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
Brief: Reviva Pharmaceuticals Holdings Reports Q2 2022 Results And Recent Business Highlights
Brief: Reviva Pharmaceuticals Provides Update On Clinical Development Pipeline
Brief: Reviva Pharmaceuticals Announces Update On Recover, A Pivotal Phase 3 Global Study Evaluating Brilaroxazine For Treatment Of Schizophrenia
Brief: Reviva Pharmaceuticals Reports Full Year 2021 Financial Results
Brief: Reviva Pharmaceuticals Announces First Patients Dosed In Pivotal Phase 3 Study
Brief: Reviva Pharmaceuticals Holdings Inc Files For Mixed Shelf Of Upto $150 Million - SEC Filing
Reviva Pharma gains as H.C. Wainwright initiates with 'buy'
U.S. STOCKS ON THE MOVE-Tilray, Moderna, Novavax, WeWork, Big Tech